THINKSABIO
Stocks Simplified

THINKSABIO NEWS

Avoro Capital Advisors: A Biotech-Focused Institution Backing Medical Innovation

Avoro Capital Advisors is a global life sciences investment firm focused mainly on biotechnology, specialty therapeutics, and healthcare innovation. The firm appears to invest in companies working on advanced treatments, novel therapies, and medical breakthroughs that can address serious unmet medical needs.

The firm was formerly known as venBio Select Advisor and is based in New York. From an investor's view, Avoro is not a broad-market institution. Its identity is strongly connected to biotech, clinical-stage companies, commercial-stage therapies, and healthcare businesses with scientific or strategic value.

Backing breakthrough science. Investing in a healthier tomorrow.

Portfolio Size and Institutional Strength

Avoro Capital Advisors has strong institutional scale in the healthcare investment space. Its latest reported 13F portfolio for Q1 2026 was around $10.16 billion, spread across roughly 32 public equity holdings. This suggests that Avoro is a highly specialized but meaningful institutional investor in the biotech and life sciences sector.

The firm's strength comes from its focused approach. Instead of spreading capital across many unrelated sectors, Avoro appears to concentrate on healthcare companies where scientific data, regulatory progress, clinical catalysts, product launches, and M&A potential can create major value. This makes Avoro's portfolio especially useful for investors who track biotech conviction.

Top Holdings and Exposure

Avoro's top reported holdings include United Therapeutics, Ascendis Pharma, Madrigal Pharmaceuticals, Krystal Biotech, and argenx. These companies suggest exposure to areas such as rare diseases, endocrine disorders, liver disease, gene therapy, immunology, and advanced therapeutic platforms.

The portfolio appears concentrated around companies with strong clinical pipelines, approved products, or important regulatory and commercial milestones. From ThinkSabio's view, this type of exposure shows that Avoro focuses on biotech names where medical innovation, trial results, FDA decisions, and strategic partnerships can play a major role in stock movement.

Leadership

Avoro Capital Advisors does not prominently present a traditional CEO role in the public sources reviewed. The key leadership figure is Dr. Behzad Aghazadeh, PhD, who serves as Managing Partner and Portfolio Manager of Avoro Capital.

Dr. Aghazadeh has more than 25 years of experience across scientific research, management consulting, institutional investing, and board leadership. His background includes a PhD in Biochemistry and Biophysics from Cornell University, which gives him a strong scientific foundation for evaluating complex biotechnology opportunities.

His experience also includes leadership involvement in Immunomedics, where he served as Executive Chairman before the company was acquired by Gilead for $21 billion in 2020. This background suggests that Avoro's investment process is not only financial, but also deeply connected to science, clinical development, and value creation within biotech companies.

Why This Institution Matters

Avoro Capital Advisors matters because biotech investing is highly complex, and specialist institutions can help investors understand where experienced healthcare-focused capital is being placed. When a firm like Avoro builds or increases positions, it may indicate confidence in a company's science, pipeline, regulatory path, or commercial opportunity.

For retail investors, tracking Avoro can provide useful signals in the healthcare sector. However, investors should not blindly copy any institution. Biotech stocks can be highly volatile because trial results, FDA updates, safety data, funding needs, and market sentiment can quickly change the investment outlook.



INSTITUTION

AVORO CAPITAL ADVISORS LLC

AVORO CAPITAL ADVISORS LLC has 100% of their portfolio invested in Healthcare stocks, and that focused bet is paying off — up +30.4% year-to-date, anchored by DFTX's +224.7% move.

Looking at their entire portfolio, the stocks AVORO CAPITAL ADVISORS LLC currently owns are averaging +30.4% so far this year, +170.3% over the past year, and +190.1% over the past 5 years (weighted by how much money they have invested in each stock). The biggest portion of the portfolio is invested in Healthcare (100.0% of holdings). Top performer this year: DFTX (+224.7%); weakest: LXEO (-50.6%).

PERFORMANCE SNAPSHOT

Quarterly | 1 Year | 5 Years

# ACTIVE STOCKS	# POSITIVE	POSITIVE %	# NEGATIVE	NEGATIVE %
27	19	70.37%	8	29.63%

Counts cover only the single quarter selected — each held stock is counted once.

QUARTERLY REVIEW

2026 Q1

AUM

$9.9B

31 Holdings | Healthcare | • Bearish

ThinkSabio View

From ThinkSabio's view, Avoro Capital Advisors appears to be an important institution for investors who want to understand high-conviction biotech investing. Its portfolio suggests exposure to companies with strong therapeutic focus, clinical progress, and potential long-term healthcare impact.

biotech and life sciences watchlists. Its holdings can help investors identify where serious institutional money is positioned, but every stock should still be studied with proper risk management, catalyst tracking, and independent research.

TS Watchlist Winners

The ThinkSabio Watchlist also produced several major winners, with some stocks delivering exceptional returns.

SHAZ — SharonAI Holdings Inc.
+52% in 10 Days
$51.31 → $78.13

HQ — Horizon Quantum Holdings Ltd.
+50% in 1 Day
$23.22 → $34.50

BLZE — Backblaze, Inc.
+64% in 6 Weeks
$7.10 → $11.66

NRIX — Nurix Therapeutics, Inc.
+16.50% in 1 Day
$19.82 → $23.09

PANW — Palo Alto Networks, Inc.
+44% in 11 Weeks
$87.43 → $126.62

These results show the strength of ThinkSabio's watchlist approach in identifying high-momentum opportunities early.

Losses of the Week

Not every stock closed the week in positive territory, as a few names witnessed minor pullbacks. However, these declines remained relatively limited when compared to the stronger upside moves seen across the watchlist and Profit Zone names, indicating that overall market momentum stayed favorable.

#IQST -15%
Not all trades win — risk managed.

TS Profit Zone Highlights

INFQ — Infleqtion, Inc.
+16%
$14.25 TO $16.59

TE — T1 Energy Inc.
+14%
$9.58 TO $10.98

SMCI — Super Micro Computer, Inc.
+10%
$33.39 TO $36.80

NOK — Nokia Oyj
+10%
$13.84 TO $14.56

ThinkSabio's Profit Zone delivered strong upside performance this week, with several tracked stocks showing notable gains from their identified levels. This reflects the platform's ability to highlight momentum opportunities before they gain broader market attention.

The strength was mainly visible across key technology, semiconductor, and AI-related names, where investor interest continues to remain strong. These sectors are benefiting from long-term themes such as AI infrastructure, advanced computing, data-center expansion, and digital transformation.

Overall, this week's Profit Zone performance highlights how structured stock tracking can help investors identify strong opportunities with better clarity. It also reinforces ThinkSabio's focus on simplifying market data and helping users stay aligned with emerging growth trends.

This Week’s Market Movers & Key Headlines

This week’s market activity was driven by strong momentum across artificial intelligence, defense technology, biotech, infrastructure, and space-related themes. Several companies announced major partnerships, product expansions, funding updates, and strategic developments, showing that investor interest remains focused on innovation-led sectors.

#GETY

Getty Images signed a multi-year agreement with OpenAI to integrate licensed visuals into ChatGPT search and visual responses.

#ONDS

Ondas secured over $40M in new autonomous defense system orders across Europe and the United States.

#MU

Micron and Anthropic announced a strategic partnership to scale next-generation AI infrastructure.

#WAVE

Eco Wave Power partnered with NVIDIA AI Digital Twins to optimize wave-energy generation.

#PALI

Positive momentum continued as PALI-2108 advanced toward Phase 2 trials for inflammatory bowel disease.

#CANF

Can-Fite received a Japanese patent for its oral anti-obesity drug, strengthening global IP protection.

#QUCY

Quantum Cyber approved a strategic equity investment in SpaceX following its Project LightShift technology agreement.

#GOOGL / #NOK

Google Cloud partnered with Nokia to bring Gemini AI models into Nokia’s Assurance Center platform.

#DELL

Dell expanded its AI Factory with NVIDIA to support next-generation HPC and enterprise AI infrastructure.

#SMCI

Supermicro introduced NVIDIA Vera Rubin NVL4-powered systems for converged AI and HPC workloads.

#WAVE

Boundless Bio agreed to merge with Serapha Bio, supported by a $230M private placement.

#QCOM / #META

Qualcomm confirmed a multi-generation AI CPU partnership with Meta for future data-center infrastructure.

#SPCX

SpaceX is reportedly exploring direct Starlink mobile service for U.S. consumers, increasing telecom competition.

#PLTR

Michael Burry has reportedly covered his short position in Palantir, according to a Substack report.

Overall, these weekly highlights show how AI adoption, defense modernization, biotech progress, and next-generation infrastructure continue to shape market sentiment. From ThinkSabio’s view, investors should track these developments closely, but also focus on company fundamentals, execution, and risk management before making any investment decisions.

Disclaimer: These stocks are based on recent earnings momentum, AI/data-center demand, semiconductor strength, energy-storage growth, and speculative photonics trends. While the catalysts are supported by recent company updates and market reports, these names remain high-risk and should be watched with proper due diligence.

Sector of the week: Healthcare



#VRAX (+2000%)

Virax Biolabs announced a **1-for-25 share consolidation** to regain Nasdaq minimum bid price compliance.

#NVCT(+84.75%)

Nuvectis Pharma recently gained attention after updates around its **NXP900 oncology program** and upcoming clinical presentations.

#DFTX (+83.63%)

Definium Therapeutics moved higher after reports highlighted a **DT120 Phase 3 win and major financing activity**.

Upcoming Week Earnings Reports to Watch

Pre Market Open

Symbol	Earnings Date
#AVAV, #CNXC	Jun 29, 2026
-	Jun 30, 2026
#GIS, #FDS, #UNF, #MSM	Jul 1, 2026
#LNN	Jul 2, 2026
-	Jul 3, 2026

After Market Close

Symbol	Earnings Date
-	Jun 29, 2026
#NKE, #STZ, #PRGS	Jun 30, 2026
#FC, #BSET, #GBX	Jul 1, 2026
-	Jul 2, 2026

Major U.S. Economic Events for Upcoming Week

Date	Event
Mon, Jun 29	Chicago PMI (Business Barometer)
Tue, Jun 30	FHFA House Price Index + JOLTS Job Openings
Wed, Jul 01	ISM Manufacturing PMI + Construction Spending
Thu, Jul 02	**Nonfarm Payrolls (June)** + Unemployment Rate + Initial Jobless Claims + Average Hourly Earnings
Fri, Jul 03	**U.S. Markets Closed (Independence Day Observed)**

Upcoming Week Recommended Stocks

#BB — BlackBerry Limited

Sector: Technology (Cybersecurity / IoT / Automotive Software)

$11.19

Recent Momentum: Explosive

Key Reasons for Potential Continuation:

BB is benefiting from strong growth in QNX automotive software, cybersecurity, and secure communications. QNX is deployed in **275M+ vehicles**, the company raised FY2027 guidance, delivered its **5th consecutive GAAP-profitable quarter**, generated its first positive Q1 operating cash flow in nine years, and expanded its **NVIDIA** partnership for Physical AI and software-defined vehicles.

#AOSL — Alpha and Omega Semiconductor Ltd.

Sector: Technology (Power Semiconductors)

$43.89

Recent Momentum: Very Strong

Key Reasons for Potential Continuation:

AOSL is benefiting from rising AI server, data center, EV, and industrial power demand. Expansion into **SiC, GaN, and Power ICs**, manufacturing growth in the U.S. and India, nearly **$190M in cash**, and increasing exposure to the **NVIDIA AI ecosystem** through leading AI server ODMs support long-term growth.

#PAYO — Payoneer Global Inc.

Sector: Technology (Cross-Border Payments / FinTech)

$7.10

Recent Momentum: Very Strong

Key Reasons for Potential Continuation:

PAYO continues to benefit from strong cross-border payment growth and improving profitability. **Nuvei's $7.40/share all-cash acquisition** provides a major catalyst, while strong B2B payment growth, raised FY2026 guidance, AI-powered financial tools, stablecoin expansion, and **88.7% institutional ownership** support the long-term outlook.

#RUN — Sunrun Inc.

Sector: Technology (Residential Solar & Distributed Energy)

$13.49

Recent Momentum: Explosive

Key Reasons for Potential Continuation:

RUN is transforming into a leading distributed energy and virtual power plant platform. Its **16GW+ VPP partnership with Tesla and Renew Home**, **43% YoY revenue growth**, record **73% battery attachment rate**, and growing AI-driven electricity demand position the company for continued expansion. The collaboration with **Tesla** strengthens Sunrun's role in powering AI data centers and grid-scale distributed energy infrastructure.

🚀"We don't predict the market. We prepare for it."

DISCIPLINE · STRATEGY · SIMPLIFIED PROFITS · THINKSABIO 2026

With these additions, ThinkSabio strengthens its position as a data-first, insight-driven platform built for modern investors. The emphasis remains on delivering clarity, consistency, and actionable intelligence in an increasingly complex market environment.

ThinkSabio — Stocks Simplified. Intelligence Amplified. 🚀